NCT06982534View on ClinicalTrials.gov

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

January 31, 2040

Conditions
Systemic Sclerosis (SSc)
Interventions
BIOLOGICAL

UTAA91 injection

CAR-modified gamma delta T cells

Trial Locations (1)

430000

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY